VFEND 200mg price in UAE

Overview

Welcome to Dwaey, specifically on VFEND 200mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Voriconazole.
VFEND 200mg is available in the market in concentration 200mg/Tablet and in the form of Tablets/Film-coated.

PFIZER EUROPE MA EEIG is the producer of VFEND 200mg and it is imported from BELGIUM, The most popular alternatives of VFEND 200mg are listed downward .

Mode Of Action

Voriconazole is a triazole antifungal agent which inhibits cytochrome P450-dependent enzymes thereby inhibiting ergosterol synthesis in fungal cell membranes. It has a broad spectrum of activity against all Candida spp. including strains resistant to fluconazole), Aspergillus spp., Scedosporium spp., and Fusarium spp.

Indication

Candidemia
Deep tissue Candida infections
Invasive aspergillosis
Scedosporiosis and Fusariosis

Precaution

Patient w/ potentially proarrhythmic conditions, risk for acute pancreatitis. Correct electrolyte disturbances e.g. hypokalaemia, hypomagnesaemia and hypocalcaemia prior to treatment. Hepatic and renal impairment. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery. Avoid intense or prolonged exposure to direct sunlight. Monitoring Parameters Monitor hepatic (prior and during treatment) and renal (during treatment) function, serum electrolytes, visual and pancreatic function. Lactation: Not known if excreted in breast milk, a decision should be made whether to discontinue nursing or drug; weigh risk/benefit

Side Effects

>10% Visual changes (photophobia
color changes
increased or decreased visual acuity
or blurred vision occur in 21%) 1-10% Tachycardia
Hypertension
Hypotension
Vasodilation
Peripheral edema
Fever
Chills
Headache
Hallucinations
Dizziness
Rash
Pruritus
Photosensitizing skin reactions
Hypokalemia
Hypomagnesemia
Nausea
Vomiting
Abdominal pain
Diarrhea
Xerostomia
Thrombocytopenia
Alkaline phosphatase increased
Serum transaminases increased
ALT/AST increased
Cholestatic jaundice
ARF

Contra indication

Hypersensitivity. Co-admin w/ CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide, quinidine, rifampicin, carbamazepine, long-acting barbiturates (e.g. phenobarbital, mephobarbital), ergot alkaloids (e.g. ergotamine and dihydroergotamine), efavirenz (?400 mg once daily), ritonavir (?400 mg bid), sirolimus, rifabutin, St John's wort.

Pregnancy and lactation

Pregnancy category: D

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Interaction

Increased prothrombin time w/ oral anticoagulants. May increase plasma concentrations of ciclosporin and tacrolimus, long-acting opiates (e.g. oxycodone, methadone), NSAIDs (e.g. ibuprofen, diclofenac), omeprazole, short-acting opiates (e.g. alfentanil, fentanyl). Decreased voriconazole plasma concentration and increased phenytoin plasma concentrations when used concomitantly. May increase plasma concentration w/ oral contraceptives. Potentially Fatal: May increase risk of QT prolongation or torsades de pointes w/ astemizole, cisapride, pimozide, quinidine and terfenadine. May increase risk of ergotism w/ ergot alkaloids (e.g. ergotamine and dihydroergotamine). May significantly increase plasma concentrations of sirolimus. Decreased plasma concentrations w/ rifampicin, carbamazepine, long-acting barbiturates (e.g. phenobarbital, mephobarbital), efavirenz (?400 mg once daily), ritonavir (?400 mg bid). Concomitant use may significantly increase rifabutin and decrease voriconazole plasma concentration.